# KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

> **NCT04034823** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 59 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **BIOLOGICAL:** KN035
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04034823
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2019-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034823, "KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04034823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*